Selected Grants
A PHASE 2A, 2-PART, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, SINGLE AND MULTIPLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AZTREONAM AND AVIBACTAM
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2024 - 2026A Phase 3, Multicenter, open-label, randomized, comparator controlled trial of the safety and efficacy of dalbavancin versus active comparator in pediatric subjects with acute bacterial skin and skin structure infections.
Clinical TrialPrincipal Investigator · Awarded by Allergan, Inc. · 2020 - 2024CAZ-AVI (Ceftazidime-Avibactam)
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2019 - 2022Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months with Suspected or Confirmed Bacterial Infection
Clinical TrialPrincipal Investigator · Awarded by Allergan, Inc. · 2016 - 2019External Relationships
- AltaThera
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.